We protect your health through science
Investigation
Measles, rubella, mumps, parvovirus B19 and rabies
Publications
Laursen CB, Davidsen JR, Van Acker L, Salzer HJF, Seidel D, Cornely OA, Hoenigl M, Alastruey-Izquierdo A, Hennequin C, Godet C, Barac A, Flick H, Munteanu O, Van Braeckel E. CPAnet Registry-An International Chronic Pulmonary Aspergillosis Registry. J Fungi (Basel). 2020 Jun
Laursen CB, Davidsen JR, Van Acker L, Salzer HJF, Seidel D, Cornely OA, Hoenigl M, Alastruey-Izquierdo A, Hennequin C, Godet C, Barac A, Flick H, Munteanu O, Van Braeckel E. CPAnet Registry-An International Chronic Pulmonary Aspergillosis Registry. J Fungi (Basel). 2020 Jun 29;6(3):E96. doi: 10.3390/jof6030096. PMID: 32610566.
PUBMED DOIProject from GEMICOMED (SEIMC) and REIPI. Molecular identification and susceptibility testing of molds isolated in a Prospective Surveillance of Triazole Resistance in Spain (FILPOP2 study). Antimicrob Agents Chemother. 2018 Jun
Alastruey-Izquierdo A*, Alcazar-Fuoli L, Rivero-Menéndez O, Ayats J, Castro C, García-Rodríguez J, Goterris-Bonet L, Ibáñez-Martínez E, Linares-Sicilia MJ, Martin-Gomez MT, Martín-Mazuelos E, Pelaez T, Peman J, Rezusta A, Rojo S, Tejero R, Vicente Anza D, Viñuelas J, Zapico MS, Cuenca-Estrella M; members of the FILPOP2 Project from GEMICOMED (SEIMC) and REIPI. Molecular identification and susceptibility testing of molds isolated in a Prospective Surveillance of Triazole Resistance in Spain (FILPOP2 study). Antimicrob Agents Chemother. 2018 Jun 25. doi: 10.1128/AAC.00358-18. PMID: 29941643.
PUBMED DOIIn vitro activity of APX001A against rare moulds using EUCAST and CLSI methodologies. J Antimicrob Chemother. 2019 May 1
Rivero-Menendez O, Cuenca-Estrella M, Alastruey-Izquierdo A.* In vitro activity of APX001A against rare moulds using EUCAST and CLSI methodologies. J Antimicrob Chemother. 2019 May 1;74(5):1295-1299. doi: 10.1093/jac/dkz022. PMID: 30753499.
PUBMED DOIIn vitro activity of olorofim (F901318) against clinical isolates of cryptic species of Aspergillus by EUCAST and CLSI methodologies. J Antimicrob Chemother. 2019 Jun 1
Rivero-Menendez O, Cuenca-Estrella M, Alastruey-Izquierdo A.* In vitro activity of olorofim (F901318) against clinical isolates of cryptic species of Aspergillus by EUCAST and CLSI methodologies. J Antimicrob Chemother. 2019 Jun 1;74(6):1586-1590. doi: 10.1093/jac/dkz078. PMID: 30891600.
PUBMED DOIAdditional Information
This group, together with the CNM Serology Laboratory (LS), houses the National Reference Laboratories for Rabies (RD 1940/2004) and Measles and Rubella (National Elimination Plan) that are integrated into the corresponding European networks. It has 10 self-developed techniques in its service portfolio (2 accredited by ENAC and 3 by the WHO). In addition, it attends to three CNM microbiological surveillance programs (measles and rubella, mumps and rabies). It is integrated into a CIBERESP group of which Juan E. Echevarría is head and in which other CNM researchers participate.
Research on MMR vaccine diseases is currently financed through an AESI project (PI15CIII/00023) of which Aurora Fernández García is co-PI and in which the LS, the CNE, the CAM (LRSP and the Epidemiology Service) and a network of primary care pediatricians participate. of the CAM.
Research on lisaviruses and other viruses associated with bats is currently funded through the VIROBAT-4 project (MINECO, SAF 2017-89355-P) of which Juan E. Echevarría is PI and in which the CNM Respiratory Viruses Laboratory, the Doñana Biological Station (CSIC) and the University of Alcalá de Henares participate.
This group, together with the CNM Serology Laboratory (LS), houses the National Reference Laboratories for Rabies (RD 1940/2004) and Measles and Rubella (National Elimination Plan) that are integrated into the corresponding European networks. It has 10 self-developed techniques in its service portfolio (2 accredited by ENAC and 3 by the WHO). In addition, it attends to three CNM microbiological surveillance programs (measles and rubella, mumps and rabies). It is integrated into a CIBERESP group of which Juan E. Echevarría is head and in which other CNM researchers participate.
Research on MMR vaccine diseases is currently financed through an AESI project (PI15CIII/00023) of which Aurora Fernández García is co-PI and in which the LS, the CNE, the CAM (LRSP and the Epidemiology Service) and a network of primary care pediatricians participate. of the CAM.
Research on lisaviruses and other viruses associated with bats is currently funded through the VIROBAT-4 project (MINECO, SAF 2017-89355-P) of which Juan E. Echevarría is PI and in which the CNM Respiratory Viruses Laboratory, the Doñana Biological Station (CSIC) and the University of Alcalá de Henares participate.